论文部分内容阅读
目的:探讨左氧氟沙星与莫西沙星在呼吸道感染患者治疗中的成本-效果。方法:选取我院2013年11月-2015年4月收治的呼吸道感染患者102例,按入院先后顺序分为对照组与观察组。对照组采用左氧氟沙星治疗,观察组采用莫西沙星治疗。结果:观察组患者临床治疗有效率为90.20%,高于对照组的84.31%,但对比无明显显著(P>0.05);观察组患者成本-效果比为8.94,对照组患者成本-效果比为15.80,对比差异显著(P<0.05)。结论:莫西沙星及左氧氟沙星在呼吸道感染患者治疗中均能取得较好治疗效果,但莫西沙星用于呼吸道感染治疗的成本-效果比优于左氧氟沙星,更具临床推广价值。
Objective: To investigate the cost-effectiveness of levofloxacin and moxifloxacin in patients with respiratory tract infection. Methods: A total of 102 patients with respiratory tract infection admitted to our hospital from November 2013 to April 2015 were selected and divided into control group and observation group according to the sequence of admission. The control group was treated with levofloxacin, and the observation group was treated with moxifloxacin. Results: The effective rate of clinical treatment in observation group was 90.20%, higher than that of control group (84.31%), but there was no significant difference (P> 0.05). The cost-effectiveness ratio was 8.94 in observation group and the cost-effectiveness ratio 15.80, the difference was significant (P <0.05). CONCLUSION: Moxifloxacin and levofloxacin are effective in treating patients with respiratory tract infection. However, the cost-effectiveness of moxifloxacin for levofloxacin treatment is superior to that of levofloxacin for clinical treatment.